| First Author | Fan LM | Year | 2022 |
| Journal | Redox Biol | Volume | 51 |
| Pages | 102269 | PubMed ID | 35276443 |
| Mgi Jnum | J:339751 | Mgi Id | MGI:7256022 |
| Doi | 10.1016/j.redox.2022.102269 | Citation | Fan LM, et al. (2022) Inhibition of endothelial Nox2 activation by LMH001 protects mice from angiotensin II-induced vascular oxidative stress, hypertension and aortic aneurysm. Redox Biol 51:102269 |
| abstractText | Endothelial oxidative stress and inflammation attributable to the activation of a Nox2-NADPH oxidase are key features of many cardiovascular diseases. Here, we report a novel small chemical compound (LMH001, MW = 290.079), by blocking phosphorylated p47(phox) interaction with p22(phox), inhibited effectively angiotensin II (AngII)-induced endothelial Nox2 activation and superoxide production at a small dose (IC50 = 0.25 muM) without effect on peripheral leucocyte oxidative response to pathogens. The therapeutic potential of LMH001 was tested using a mouse model (C57BL/6J, 7-month-old) of AngII infusion (0.8 mg/kg/d, 14 days)-induced vascular oxidative stress, hypertension and aortic aneurysm. Age-matched littermates of p47(phox) knockout mice were used as controls of Nox2 inhibition. LMH001 (2.5 mg/kg/d, ip. once) showed no effect on control mice, but inhibited completely AngII infusion-induced excess ROS production in vital organs, hypertension, aortic walls inflammation and reduced incidences of aortic aneurysm. LMH001 effects on reducing vascular oxidative stress was due to its inhibition of Nox2 activation and was abrogated by knockout of p47(phox). LMH001 has the potential to be developed as a novel drug candidate to treat oxidative stress-related cardiovascular diseases. |
